Testing for cancer risk genes in children with newly diagnosed cancer
Assessment of the Utility of Family-based (Trio) Whole-genome Sequencing for Cancer Predisposition Testing in Sequential Newly Diagnosed Paediatric and Adolescent Cancer Patients
This study is testing whether a family-based genetic test can help find cancer risk genes in children and teens who have just been diagnosed with cancer.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 270 (estimated) |
| Ages | N/A to 21 Years |
| Sex | All |
| Sponsor | Sydney Children's Hospitals Network Academic / other |
| Locations | 3 sites (Newcastle, New South Wales and 2 other locations) |
| Trial ID | NCT04903782 on ClinicalTrials.gov |
What this trial studies
This study assesses the effectiveness of family-based whole-genome sequencing (WGS) to identify cancer predisposition syndromes in children and adolescents newly diagnosed with cancer. By analyzing the genetic information of the patient and their family, the study aims to uncover germline mutations that may increase cancer risk. The research will evaluate the clinical benefits of this approach compared to traditional predictive methods, focusing on its impact on patient care and genetic counseling. The study also aims to explore the psychosocial effects of genetic testing on patients and their families.
Who should consider this trial
Good fit: Ideal candidates for this study are children and adolescents aged 21 years or younger who have been newly diagnosed with cancer.
Not a fit: Patients who do not have a new diagnosis of malignancy or are older than 21 years may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved identification of cancer predisposition in children, enhancing early intervention and personalized care.
How similar studies have performed: While the approach of using whole-genome sequencing for cancer predisposition testing is gaining traction, the specific application in pediatric populations is still relatively novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
* New diagnosis of malignancy * Age ≤ 21 years * Written informed consent Psychosocial component: * Participants (≥ 12 years) * Parent/caregiver(s) of participants * Healthcare professionals involved in the care of patients enrolled in the study
Where this trial is running
Newcastle, New South Wales and 2 other locations
- John Hunter Children's Hospital — Newcastle, New South Wales, Australia (Recruiting)
- Sydney Children's Hospital — Sydney, New South Wales, Australia (Recruiting)
- The Children's Hospital at Westmead — Sydney, New South Wales, Australia (Recruiting)
Study contacts
- Study coordinator: Clinical Trials Manager
- Email: SCHN-PREDICT@health.nsw.gov.au
- Phone: +61 2 9382 3122
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.